Low prevalence of active cytomegalovirus infection in a cardiovascular intensive care unit by Haruhiko Ishioka et al.
Ishioka et al. Journal of Intensive Care 2014, 2:12
http://www.jintensivecare.com/content/2/1/12LETTER TO THE EDITOR Open AccessLow prevalence of active cytomegalovirus infection
in a cardiovascular intensive care unit
Haruhiko Ishioka1*, Masamitsu Sanui1, Yusuke Tsutsumi1,2, Fumitaka Yanase1 and Junji Shiotsuka1Abstract
Active cytomegalovirus infection is not uncommon in critically ill non-immunosuppressed patients. We conducted a
preliminary observational study to determine the prevalence of active cytomegalovirus infection in cardiovascular
surgical patients. One hundred patients admitted to the intensive care unit following cardiovascular surgery were
enrolled between January 2010 and May 2010. Four patients (4%) were positive for serum pp65 antigens, though
cytomegalovirus-positive serology (immunoglobulin G, IgG) was found in 98 patients (98%) including those four
patients. Active cardiac diseases and their operative procedures including cardiopulmonary bypass may not be
significant risk factors for active cytomegalovirus infection unless systemic derangements are also present.
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Active cytomegalovirus (CMV) infection, diagnosed by
one of the following examinations for CMV, either pp65
antigen, polymerase chain reaction, or viral culture, is not
as uncommon in critically ill non-immunosuppressed
patients, as previously thought [1]. Recent studies have
also shown that CMV infection may play a role in the
progression of cardiovascular diseases [2,3]. Although
there are several reports about an association of CMV
virus infection with active cardiovascular conditions
[4,5], the existence of this association is still uncertain.
We therefore conducted a preliminary observational study
to determine the prevalence of active CMV infection in
cardiovascular surgical patients.
Methods and results
One hundred patients admitted to our intensive care
unit (ICU) following cardiovascular surgery between
January 2010 and May 2010 were enrolled. Serum pp65
antigens for CMV at ICU admission, day 7, and day 14
were evaluated. A serum pp65 antigen-positive was
defined as ≥1 cell per 100,000 leukocytes. CMV serology
(immunoglobulin G, IgG) tests were also performed on ad-
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obtained from patients. Statistical analysis was performed
with Stata V13. The differences in characteristics were
tested using Fisher’s exact test for categorical variables
and the Wilcoxon test for continuous variables.
Four of 100 patients (4.0%) were positive for serum pp65
antigens, while CMV-positive serology (IgG) was found in
98 patients (98.0%) including those four patients. Thus,
the incidence of reactivation was 4.1% among IgG-positive
patients. The demographic details of all IgG-positive
patients are outlined in Table 1. Characteristics of antigen-
positive patients included: patient 1 had a history of
rheumatic arthritis on long-term corticosteroids, who
underwent elective aortic valve replacement with peri-
operative steroid supplementation; patient 2 had a diagno-
sis of native-valve endocarditis due to methicillin-resistant
Staphylococcus aureus (MRSA), which required emergency
aortic valve replacement; patient 3 underwent Y graft
replacement, complicated with postoperative acute kidney
injury (AKI) due to left gluteal muscle ischemia and
rhabdomyolysis; Patient 4 had a history of receiving adju-
vant chemotherapy with orally active fluoropyrimidine
against residual gastric cancer, who underwent off-pump
coronary artery bypass grafting before radical gastrectomy.
Patients 2 and 4 had positive pp65 antigens at ICU admis-
sion, while patient 1 became positive on day 7, and patient
3 became positive on day 14. Quantitative values of pp65
antigenemia were 1 positive per 100,000 leukocytes in allLtd. This is an Open Access article distributed under the terms of the Creative
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Table 1 Demographics of CMV IgG-positive patients
Negative CMV infection (n = 94) Positive CMV infection (n = 4) P valuea
Age, mean ± SD 66.7 ± 10.2 68.5 ± 7.1 0.727
Female gender, n (%) 22 (23) 2 (50) 0.251
Comorbidities
Hypertension, n (%) 61 (65) 3 (75) 1.000
Diabetes mellitus, n (%) 25 (27) 0 0.570
Chronic kidney disease (stage 5), n (%) 10 (11) 1 (25) 0.384
Malignancy, n (%) 1 (1) 1 (25) 0.080
Preoperative severe infection, n (%) 0 1 (25) 0.041
Recent corticosteroid use (<1 mo), n (%) 0 1 (25) 0.041
Duration of operation (min), median (IQR) 328 (275–393) 315 (259–415) 0.993
Duration of cardiopulmonary bypass (min), median (IQR) 130 (0–172) 53 (0–118) 0.194
APACHE II scores, median (IQR) 16.0 (12.0–19.0) 18.5 (11.5–20.5) 0.559
Length of ICU stay (day), median (IQR) 3.0 (3.0–5.0) 5.0 (3.5–8.0) 0.179
Length of postoperative stay (day), median (IQR) 15.0 (13.3–21.0) 19.0 (18.0–43.0) 0.090
In-hospital mortality, n (%) 1 (1) 0 1.000
APACHE, acute physiology and chronic health evaluation; IQR, interquartile range. aFisher’s exact test for categorical variables, Wilcoxon test for
continuous variables.
Ishioka et al. Journal of Intensive Care 2014, 2:12 Page 2 of 3
http://www.jintensivecare.com/content/2/1/12of four patients. No clinically significant changes in
positive cell counts were detected up to day 14 in either
patient. No clinical signs or symptoms of end-organ dis-
ease were seen during the postoperative course among
these four patients, and no specific treatment was given
after positive pp65 antigen testing. All antigen-positive
patients except patient 3 received intraoperative blood
transfusion. The median number of acute physiology
and chronic health evaluation (APACHE) II scores on ad-
mission in those four patients were similar to the antigen-
negative patients (18.5 [interquartile range (IQR), 8.8–20.8]
vs 16.0 [IQR, 12.0–19.0]). One of the antigen-negative
patients died during the hospital stay.
Discussion
According to these preliminary results, a few cardiovas-
cular surgical patients have active CMV infection despite
the high prevalence of CMV IgG antibody in the periopera-
tive period. CMV reactivation is often induced by immuno-
suppressive process such as AIDS or immunosuppressive
therapies for solid organ and hematopoietic stem cell
transplantation, but in critically ill non-immunosuppressed
patients, immunological derangement associated with crit-
ical illness, so-called immunoparalysis, can reactivate CMV
[1,6]. Each patient with active CMV infection in this study
had each risk factor including steroid use, severe infection,
postoperative AKI, or chemotherapy. The presence of these
known risk factors could influence the immunological
status of the patients. Chemotherapy could induce CMV
reactivation [7]. Steroid exposure in the ICU could be a
potential reactivation trigger as well [8]. Timing of the first
positive results for pp65 antigen in those patients mightbe related to the duration of their underlying diseases and
the severity, presumably because CMV requires a substan-
tial time period to proceed from the latent phase to active
infection. Intraoperative transfusion could have induced
their positive result, especially for the two patients who
were antigen-positive at the time of ICU admission,
although filtered leukocyte-reduced blood products, which
may reduce the risk of CMV transmission [9], have been
used in our hospital. The limitations of this preliminary
study are the small number of patients and a relatively
short length of the study period. Optimal monitoring
should have been more than 21 days to detect later reacti-
vations according to previous results [5].
The low prevalence of active CMV infection in this
study population could suggest relatively low patient
severity, reflected by a median APACHE II score of 16.
According to a subgroup analysis of the previous system-
atic review [1], a low prevalence of active CMV infection
was confirmed in non-immunosuppressed intensive care
unit patients with relatively low disease severity. Active
cardiac diseases and their operative procedures including
cardiopulmonary bypass may not be risk factors for active
CMV infection unless systemic derangements are also
present.Abbreviations
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